Results 31 to 40 of about 5,494 (193)
Alzheimer’s disease: the controversial approval of Aducanumab [PDF]
Neurological Sciences, 2021 n ...
Tagliavini, Fabrizio +2 more
openaire +2 more sources
CPT: Pharmacometrics & Systems Pharmacology, 2022 Aducanumab is a human immunoglobulin G1 anti‐amyloid beta (Aβ) antibody currently being evaluated for potential treatment of patients with early Alzheimer’s disease.
Kumar Kandadi Muralidharan +6 more
doaj +1 more source
Aducanumab: an uprising hope with vague horizons
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2023 Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Amyloid-beta (Aβ) deposition, is one of the processes involved in the pathophysiology of AD, has inspired interest in targeted therapies, including monoclonal antibodies.
Delara Hazegh Fetratjoo +2 more
doaj +1 more source
Aducanumab- a Drug of hope for the elderly
Journal of the Pakistan Medical Association, 2022 Madam, Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by impaired cognitive functions in a person (1). It is the most common cause of dementia and a major cause of morbidity and mortality in the elderly. Currently, 50 million people in the world live with dementia, AD accounting for more than half (50-75%) of all ...
Muhammad Kashan, Zaheer +2 more
openaire +2 more sources
CPT: Pharmacometrics & Systems Pharmacology, 2022 Alzheimer's disease (AD) is an irreversible, progressive brain disorder that impairs memory and cognitive function. Dysregulation of the amyloid‐β (Aβ) pathway and amyloid plaque accumulation in the brain are hallmarks of AD.
Lin Lin +9 more
doaj +1 more source
Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in the Era of Disease-Modifying Treatments
Brain Sciences, 2021 Correct in vivo diagnosis of Alzheimer’s disease (AD) helps to avoid administration of disease-modifying treatments in non-AD patients, and allows the possible use of such treatments in clinically atypical AD patients.
George P. Paraskevas, Elisabeth Kapaki
doaj +1 more source
Making the Case for Accelerated Withdrawal of Aducanumab [PDF]
Journal of Alzheimer's Disease, 2022 The controversial approval in June 2021 by the Food and Drug Administration (FDA) of aducanumab (marketed as Aduhelm), Biogen’s monoclonal antibody for patients with Alzheimer’s disease, raises significant concerns for the dementia field and drug approval process, considering its lack of adequate evidence for clinical efficacy, safety issues, and cost.
Whitehouse, Peter +16 more
openaire +4 more sources
How Will Aducanumab Approval Impact AD Research?
, 2021 This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source.
Saykin, A. J. +27 more
core +1 more source
Aducanumab and lecanemab – two novel antibodies against pathologic species of amyloid beta in the treatment of Alzheimer’s disease [PDF]
Farmacja Polska, 2023 Alzheimer's disease (AD) is the most common cause of dementia worldwide. According to the widely accepted theory, it is caused by neurodegeneration initiated by the deposition of a pathological protein, amyloid β, in the brain. Amyloid β can aggregate to
Jakub Wojcieszak
doaj +1 more source
Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Clinical Interventions in Aging, 2022 Miguel Vaz,1 Vítor Silva,1 Cristina Monteiro,2 Samuel Silvestre1,3 1CICS-UBI - Health Sciences Research Centre, Faculty of Health Sciences, University of Beira Interior, Covilhã, 6200-506, Portugal; 2UFBI – Pharmacovigilance Unit of Beira Interior ...
Vaz M, Silva V, Monteiro C, Silvestre S
doaj